Aprotinin attenuates genomic expression variability following cardiac surgery

Journal of Cardiac Surgery

Volumn 24, Issue 6, 2009, Pages 772-780

  Ramlawi, Basel ^a   Otu, Hasan ^c   Russo, Mark J ^a   Novick, Richard J ^d   Bianchi, Cesario ^b   Sellke, Frank W ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA;

AGED; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CELL ADHESION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HUMAN; LOADING DRUG DOSE; MALE; OUTCOME ASSESSMENT; PEROPERATIVE CARE; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; UPREGULATION; VALVULOPLASTY;

AGED; AMINOCAPROIC ACIDS; APOPTOSIS; APROTININ; CARDIOPULMONARY BYPASS; CELL ADHESION; COHORT STUDIES; CORONARY ARTERY BYPASS; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HEART VALVE PROSTHESIS IMPLANTATION; HEMOSTATICS; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NF-KAPPA B; PREMEDICATION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 70449474474     PISSN: 08860440     EISSN: 15408191     Source Type: Journal    
DOI: 10.1111/j.1540-8191.2009.00924.x     Document Type: Article

References (36)

1. Mannucci PM : Hemostatic drugs. N Engl J Med 1998 339 : 245 253.
2. Landis RC, Asimakopoulos G, Poullis M, et al : Effect of aprotinin (trasylol) on the inflammatory and thrombotic complications of conventional cardiopulmonary bypass surgery. Heart Surg Forum 2001 4 (Suppl 1 S35 S39.
3. Mahdy AM, Webster NR : Perioperative systemic haemostatic agents. Br J Anaesth 2004 93 : 842 858.
4. Asimakopoulos G, Lidington EA, Mason J, et al : Effect of aprotinin on endothelial cell activation. J Thorac Cardiovasc Surg 2001 122 : 123 128.
5. Iwata Y, Nicole O, Okamura T, et al : Aprotinin confers neuroprotection by reducing excitotoxic cell death. J Thorac Cardiovasc Surg 2008 135 : 573 578 discussion 578.
6. Khan TA, Bianchi C, Voisine P, et al : Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J Thorac Cardiovasc Surg 2004 128 : 602 608.
7. Murkin JM. Cardiopulmonary bypass and the inflammatory response: A role for serine protease inhibitors? J Cardiothorac Vasc Anesth 1997 11 (2 Suppl 1 19 23 discussion 24-15.
8. Hayashida N, Isomura T, et al : Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg 1997 114 : 261 269.
9. Sedrakyan A, Treasure T, Elefteriades JA : Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004 128 : 442 448.
10. Westaby S, Katsumata T. Aprotinin and vein graft occlusion - the controversy continues. J Thorac Cardiovasc Surg 1998 116 : 731 733.
11. Karkouti K, Beattie WS, Dattilo KM, et al : A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion 2006 46 : 327 338.
12. Mangano DT, Tudor IC, Dietzel C : The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006 354 : 353 365.
13. Mangano DT, Rieves RD, Weiss KD : Judging the safety of aprotinin. N Engl J Med 2006 355 : 2261 2262.
14. Mangano DT, Miao Y, Vuylsteke A, et al : Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007 297 : 471 479.
15. Westaby S : Aprotinin: Twenty-five years of claim and counterclaim. J Thorac Cardiovasc Surg 2008 135 : 487 491.
16. Sundt TM : The demise of aprotinin: Our share of the blame. J Thorac Cardiovasc Surg 2008 135 : 729 731.
17. Poullis M, Landis RC, Taylor KM : Aprotinin: Is it prothrombotic? Perfusion 2001 16 : 401 409.
18. Landis RC, Asimakopoulos G, Poullis M, et al : The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg 2001 72 : 2169 2175.
19. Ramlawi B, Otu H, Rudolph JL, et al : Genomic expression pathways associated with brain injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg 2007 134 : 996 1005.
20. Murkin JM, Newman SP, Stump DA, et al : Statement of consensus on assessment of neurobehavioral outcomes after cardiac surgery. Ann Thorac Surg 1995 59 : 1289 1295.
21. Mack WJ, Freed DM, Williams BW, et al : Boston Naming Test: Shortened versions for use in Alzheimer's disease. J Gerontol 1992 47 : P154 P158.
22. Yuen T, Wurmbach E, Pfeffer RL, et al : Accuracy and calibration of commercial oligonucleotide and custom cDNA microarrays. Nucleic Acids Res 2002 30 : e48.
23. Rudolph JL, Babikian VL, Birjiniuk V, et al : Atherosclerosis is associated with delirium after coronary artery bypass graft surgery. J Am Geriatr Soc 2005 53 : 462 466.
24. Jones J, Otu H, Spentzos D, et al : Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005 11 : 5730 5739.
25. Li C, Wong WH : Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci USA 2001 98 : 31 36.
26. Barash Y, Dehan E, Krupsky M, et al : Comparative analysis of algorithms for signal quantitation from oligonucleotide microarrays. Bioinformatics 2004 20 : 839 846.
27. Irizarry RA, Bolstad BM, Collin F, et al : Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003 31 (4 e15.
28. Shedden K, Chen W, Kuick R, et al : Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. BMC Bioinformatics 2005 6 : 26.
29. Ramalho-Santos M, Yoon S, Matsuzaki Y, et al : "Stemness": Transcriptional profiling of embryonic and adult stem cells. Science 2002 298 : 597 600.
30. Zhang B, Schmoyer D, Kirov S, et al : GOTree Machine (GOTM): A web-based platform for interpreting sets of interesting genes using gene ontology hierarchies. BMC Bioinformatics 2004 5 : 16.
31. Greilich PE, Brouse CF, Whitten CW, et al : Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: A randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 2003 126 : 1498 1503.
32. Sedrakyan A, Wu A, Sedrakyan G, et al : Aprotinin use in thoracic aortic surgery: Safety and outcomes. J Thorac Cardiovasc Surg 2006 132 : 909 917.
33. Sodha NR, Boodhwani M, Bianchi C, et al : Aprotinin in cardiac surgery. Expert Rev Cardiovasc Ther 2006 4 : 151 160.
34. Rossi A, Elia G, Santoro MG : Activation of the heat shock factor 1 by serine protease inhibitors. An effect associated with nuclear factor-kappaB inhibition. J Biol Chem 1998 273 : 16446 16452.
35. Buerke M, Pruefer D, Sankat D, et al : Effects of aprotinin on gene expression and protein synthesis after ischemia and reperfusion in rats. Circulation 2007 116 (11 Suppl I121 I126.
36. Apeler H, Peters J, Schroder W, et al : Expression, purification, biochemical and pharmacological characterization of a recombinant aprotinin variant. Arzneimittelforschung 2004 54 : 483 497.